Assembly Biosciences, Inc. / Fundamentals
Income statement
- Net revenue
€20.35M - Cost of goods sold
€0.00 - Gross profit
€20.32M - SG&A expenses
€15.51M - R&D expenses
€50.63M - EBITDA
-€37.41M - D&A
€84.43K - EBIT
-€37.50M - Interest expenses
€0.00 - EBT
-€33.63M - Tax expenses
-€65.48K - Net income
-€33.57M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€25.41M - Changes in working capital
€21.32M - Operating cash flow
-€48.12M - Capex
€0.00 - Other investing cash flow
€3.40M - Net investing cash flow
€35.64M - Total cash dividends paid
€0.00 - Issuance of common stock
€16.16M - Debt repayment
€0.00 - Other financing cash flow
-€10.29M - Net financing cash flow
€16.61M - Foreign exchange effects
€0.00 - Net change in cash
€4.13M - Cash at end of period
€20.68M - Free cash flow
-€48.12M
Balance sheet
- Cash and cash equivalents
€20.68M - Cash and short-term investments
€64.60M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€2.14M - Total current assets
€66.74M - Property, plant & equipment
€2.59M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€268.80K - Total non-current assets
€2.85M - Total assets
€69.60M - Accounts payable
€640.13K - Short-term debt
€459.21K - Other current liabilities
€4.39M - Total current liabilities
€40.74M - Long-term debt
€2.03M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€11.23M - Total non-current liabilities
€13.26M - Total liabilities
€54.00M - Common stock
€6.89K - Retained earnings
-€727.96M - Other equity
-€240.37K - Total equity
€15.59M - Total liabilities and shareholders' equity
€69.60M
Company information
- Market capitalization
€112.77M - Employees
73 - Enterprise Value
€110.90M
Company ratios
- Gross margin
-
99.9% Much better than peer group: -3,276,615,745,013.0% - EBITDA margin
-
-183.8% Much better than peer group: -7,750,836,282,718.0% - EBIT margin
-
-184.3% Much better than peer group: -8,196,187,584,510.0% - EBT margin
-
-165.3% Much better than peer group: -7,865,186,473,517.7% - Net margin
-
-165.0% Much better than peer group: -7,865,186,473,513.8% - ROE
-
-215.3% Much worse than peer group: -105.6% - ROA
-
-48.2% Worse than peer group: -32.0% - Asset turnover
-
29.2% Better than peer group: 12.2% - FCF margin
-
-236.4% Much better than peer group: -6,552,513,311,474.0% - FCF yield
-42.7% - Efficiency ratio
283.8% - Net sales per employee
-
€278.78K - Net income per employee
-
-€459.85K